Serif Targets Safer DNA Therapeutics
April 21, 2026
Flagship Pioneering-backed Serif Biomedicines debuts with $50M to develop modified DNA therapies combining mRNA and gene therapy advantages.
April 21, 2026
Flagship Pioneering-backed Serif Biomedicines debuts with $50M to develop modified DNA therapies combining mRNA and gene therapy advantages.